Safety and effectiveness of pirfenidone combined with carboplatin‐based chemotherapy in patients with idiopathic pulmonary fibrosis and non‐small cell lung cancer: A retrospective cohort study

Abstract

SIGNIFICANT FINDINGS OF THE STUDY: No patients with IPF and NSCLC who received pirfenidone in combination with first-line carboplatin-based chemotherapy or late-line ICIs developed acute IPF exacerbations. What this study adds Pirfenidone might have a prophylactic effect against chemotherapy-associated AE-IPF.